Jannell DePalantino, PharmD

Vice President, Head of US Field Medical at Stemline Therapeutics

Jannell DePalantino, PharmD has extensive work experience in the pharmaceutical industry. Jannell currently holds the position of Chief Member at Chief, a private membership network for women executives. In this role, they focus on connecting and supporting women executive leaders to strengthen their leadership skills and magnify their influence.

Prior to their current position, DePalantino worked at Stemline Therapeutics as the Vice President, Head of US Field Medical. Jannell also held the position of Executive Director, Solid Tumor MSLs at the same company. At Stemline Therapeutics, they played a crucial role in leading the US field medical team and overseeing the solid tumor MSLs.

DePalantino's earlier experience includes working at The Janssen Pharmaceutical Companies of Johnson & Johnson. Jannell held various roles such as National Director, Oncology Clinical Educator Team (Commercial), Scientific Director, Hematology Oncology MSL Team, Field Director, Oncology MSL Team- Solid Tumor and Hematology, Associate Director, Medical Affairs Strategic Trials- Oncology, Sr. Medical Science Liaison, Immunology/Gastroenterology, Medical Science Liaison, Nephrology, and Drug Information Resident.

Throughout their career, DePalantino has demonstrated their ability to build and lead teams, execute launch strategies, and foster strong relationships with customers. Jannell'sexpertise lies in the fields of oncology, hematology, immunology, gastroenterology, and nephrology.

Jannell DePalantino, PharmD pursued their education in a chronological manner. Prior to earning their Doctor of Pharmacy (PharmD) degree from the University of the Sciences in Philadelphia in 2004, they completed their Bachelor of Science (B.S.) in Psychology at Arizona State University in 1998. These are the only educational experiences provided, and no further assumptions should be made.

Links

Timeline

  • Vice President, Head of US Field Medical

    September, 2022 - present

  • Executive Director, Solid Tumor MSLs

    April, 2022

View in org chart